| Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED |
2020-09-22 |
| Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures |
2020-09-17 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC |
2020-09-03 |
| Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares |
2020-08-19 |
| Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED |
2020-08-13 |
| F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures |
2020-08-12 |
| F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors |
2020-08-12 |
| Oasmia–Consilium: public relations, 202008 service existent by CSC |
2020-08-10 |
| Reapplix–Denmark (govt): investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Vaekstfonden |
2020-07-14 |
| Reapplix–Lauxera Capital: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Lauxera Capital Partners |
2020-07-14 |
| Reapplix–MK Ventures: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor MK Ventures |
2020-07-14 |
| Reapplix–North East Health Care: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor North East Health Care |
2020-07-14 |
| Reapplix–Novo Group: investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Novo Holdings |
2020-07-14 |
| Reapplix–PERSON: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Bo Jesper Hansen |
2020-07-14 |
| Reapplix–PERSON: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Jan Struve |
2020-07-14 |
| Reapplix–SEVERAL: investment, 202007 financing round DKK150m ($22.6m) from new + existing investors |
2020-07-14 |
| Eir Ventures–Denmark (govt): investment, 202007 first closing totalling €76m incl investor Vaekstfonden |
2020-07-10 |
| Eir Ventures–EU (govt): investment, 202007 first closing totalling €76m incl investor EIF |
2020-07-10 |
| Eir Ventures–Novo Group: investment, 202007 first closing totalling €76m incl investor Novo Holdings |
2020-07-10 |
| Eir Ventures–Optimum Strategic Communications: public relations, 202007 service existent by Optimum |
2020-07-10 |
| Eir Ventures–SEVERAL: investment, 202007 first closing €76m from Saminvest + EIF + Vaekstfonden + Novo Holdings + private investors |
2020-07-10 |
| Eir Ventures–Sweden (govt): investment, 202007 first closing totalling €76m incl investor Saminvest |
2020-07-10 |
| VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital |
2020-07-08 |
| Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund |
2020-07-03 |
| Freeline Therapeutics–Novo Group: investment, 202006 financing round Series C final closing totalling $80m incl co-lead investor Novo Holdings A/S |
2020-06-30 |
| Freeline Therapeutics–SEVERAL: investment, 202006 financing round Series C final closing $80m (£61.2m) co-led by Novo Holdings + Eventide + Wellington |
2020-06-30 |
| JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV |
2020-06-12 |
| Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics |
2020-06-11 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications |
2020-06-08 |
| NodThera–Novo Group: investment, 202006 financing round Series B totalling £44m ($55m) incl lead investor Novo Ventures |
2020-06-03 |
| NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures |
2020-06-03 |
| Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility |
2020-05-27 |
| Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital |
2020-05-26 |
| Kaiku Health–Elekta: investment, 202005 acquisition 100% of Kaiku Health by Elekta |
2020-05-15 |
| Calliditas Therapeutics–SEVERAL: investment, 202005–202006 private placement SEK82.9m with 924k common shares at SEK89.7/share outside US |
2020-05-14 |
| Calliditas Therapeutics–SEVERAL: investment, 202005–202007 US IPO $81m+$6.9m with w 8.3m+707k common shares as ADSs at Nasdaq Global Market |
2020-05-14 |
| Oncopeptides–SEVERAL: investment, 202005 directed share issue SEK1.414b ($144m) with 12.295m new shares at SEK115/share |
2020-05-05 |
| EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners |
2020-04-22 |
| EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund |
2020-04-22 |
| Leo Pharma–Oneness Biotech: therapeutic antibody, 202004– license ww excl to FB825 $40m upfront + $530m milestones + royalties from Oneness + MBS |
2020-04-15 |
| Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–Lazard: financial services, 202004 supply service Lazard financial advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–McDermott Will & Emery: legal services, 202004 supply service MWE legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Plesner: legal services, 202004 supply service Plesner AP legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Rothschild & Co: financial services, 202004 supply service Rothschild & Co financial advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Servier: investment, 202004–202006 acquisition 100% €na |
2020-04-03 |
| Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments |
2020-03-31 |
| Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche |
2020-03-31 |
| Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings |
2020-03-13 |
| Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price |
2020-03-13 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology |
2020-03-02 |
| Genmab–Genedata: bioinformatics, 202002 supply existent Genmab is existing customer of Genedata |
2020-02-26 |
| InstruNor–Fluidigm: investment, 202002 acquisition $7.2m with $5.2m in cash + $2m in stock |
2020-02-26 |
| Lundbeck–Genedata: bioinformatics, 202002 supply existent Lundbeck is existing customer of Genedata |
2020-02-26 |
| Merus–Genedata: bioinformatics, 202002 supply existent Merus is existing customer of Genedata |
2020-02-26 |
| Novo Group–Genedata: bioinformatics, 202002 supply existent Novo Nordisk is existing customer of Genedata |
2020-02-26 |
| Novo Group–Genedata: bioinformatics, 202002 supply existent Novozymes is existing customer of Genedata |
2020-02-26 |
| FinnGen–AbbVie: genomics, 202002 collab existent AbbVie is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–AstraZeneca: genomics, 202002 collab existent AstraZeneca is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Biogen: genomics, 202002 collab existent Biogen is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–BMS: genomics, 202002 collab existent BMS is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–JnJ: genomics, 202002– collab Janssen new industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Maze Therapeutics: genomics, 202002– collab Maze new industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m |
2020-02-21 |
| Orphazyme–SEVERAL: investment, 202002 directed issue + private placement DKK745m (€100m) of 7m new + existing shares |
2020-02-07 |
| Servier–Saga Diagnostics: pharmacogenomic services, 202001–202201 collab extension 2y services usingSAGAsafe technology in cancer studies |
2020-01-28 |
| Blueprint Genetics–Quest Diagnostics: investment, 202001 acquisition €na by Quest Diagnostics |
2020-01-22 |
| HepaRegenix–Novo Group: investment, 202001 financing round Series B totalling €11m incl existing investor Novo Seeds |
2020-01-21 |
| HepaRegenix–SEVERAL: investment, 202001 financing round Series B €11m with BIVF + Novo Holdings + HTGF + Coparion + Ascenion |
2020-01-21 |
| Nanoform–Coulter Partners: recruitment services, 202001 supply service placement of Sally Langa as new head of US Sales at Nanoform |
2020-01-21 |
| Biograil–High-Tech Gründerfonds: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl lead investor HTGF |
2020-01-15 |
| Biograil–Megatrend Invest: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl co-investor Megatrend Invest A/S |
2020-01-15 |
| Biograil–OTHER: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl a Danish private healthcare investor |
2020-01-15 |
| Biograil–SEVERAL: investment, 202001 seed financing round €3m (potentially up to €5m) led by HTGF |
2020-01-15 |
| Biograil–Swiss Investment Group: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl co-investor Swiss Investment Group |
2020-01-15 |
| NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio |
2020-01-08 |
| PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED |
2020-01-07 |
| VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund |
2020-01-06 |
| Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis |
2020-01-06 |
| Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS |
2019-12-20 |
| CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance |
2019-12-19 |
| Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies |
2019-12-19 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo-2019.png){kind=logo}
Date![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
